Analyse
31. Aug. 2026•1 Min. Lesezeit
AstraZeneca pays $200M upfront to Sino Biopharma for PDE3/4 inhibitor rights
AstraZeneca has paid $200 million to Sino Biopharmaceutical and secured non‑China rights to PDE3/4 inhibitor TQC3721, aiming to develop a COPD candidate against Merck’s Ohtuvayre.
Analyse
23. Aug. 2026•1 Min. Lesezeit
Where to Source Semaglutide: Supplier Guide
A concise guide to the 95 Semaglutide suppliers on Pharmacountry, highlighting key sourcing regions and buyer considerations.
3
1
Analyse
23. Aug. 2026•1 Min. Lesezeit
Which Countries Dominate Manufacturing Equipment & Utilities Supply?
China, India, Italy, Germany, and the United States together account for over two‑thirds of active suppliers in Manufacturing Equipment & Utilities on Pharmacountry.
1